Helen Farr, a Partner at Taylor Wessing, discusses the hurdles that life science businesses must tackle to bring employees back to work safely; whether that be working remotely or returning to the lab.
List view / Grid view
Filter the results
The Access to COVID-19 Tools (ACT) Accelerator reports that new agreements have made millions of rapid COVID-19 antigen tests available to low and middle-income countries.
US outsourcing organisation GRAM is set to undertake the aseptic fill and finish manufacture of J&J's COVID-19 vaccine candidate.
Due to the demand caused by the COVID-19 pandemic, the UK government has said British manufacturers will produce the majority of PPE by the end of the year.
A new report has said that CROs are likely to resume their business activity in the second half of 2020 because of high demand.
Researchers suggest, based on certain exclusions, older people are likely to be underrepresented in 50 percent of COVID-19 trials and all vaccine trials in the US.
A review suggests some large pharma companies were approved to receive paycheck protection program (PPP) loans that were intended to help small US businesses to pay workers during the COVID-19 pandemic.
The trial will evaluate the safety and efficacy of the Novavax’ NVX-CoV2373 vaccine candidate in approximately 10,000 UK participants.
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
A Phase III clinical trial to evaluate J&J's COVID-19 vaccine in multiple countries has enrolled its first patients.
A contract for 300 doses of the investigational COVID-19 vaccine candidate has been signed by the European Commission (EC).
An Emergency Use Authorization (EUA) request for the use of RLF-100™ (aviptadil) in critical COVID-19 patients was submitted to the US FDA.
As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.
Researchers who designed a transmission model for COVID-19 demonstrated that attempting to establish herd immunity against COVID-19 would be too challenging.
Operation Warp Speed and the NIH are funding the expansion of two trials evaluating the efficacy of convalescent plasma therapy in hospitalised COVID-19 patients.